医学
克拉斯
胰腺癌
内科学
突变
癌症
胰腺
癌症研究
结直肠癌
遗传学
生物
基因
作者
John H. Strickler,Hironaga Satake,Thomas J. George,Rona Yaeger,Antoine Hollebecque,Ignacio Garrido‐Laguna,Martin Schüler,Timothy F. Burns,Andrew L. Coveler,Gerald S. Falchook,Mark Vincent,Yu Sunakawa,Laëtitia Dahan,David L. Bajor,Sun Young Rha,Charlotte Lemech,Dejan Juric,Marko Rehn,Gataree Ngarmchamnanrith,Pegah Jafarinasabian,Qui Tran,David S. Hong
标识
DOI:10.1056/nejmoa2208470
摘要
KRAS p.G12C mutation occurs in approximately 1 to 2% of pancreatic cancers. The safety and efficacy of sotorasib, a KRAS G12C inhibitor, in previously treated patients with KRAS p.G12C–mutated pancreatic cancer are unknown.
科研通智能强力驱动
Strongly Powered by AbleSci AI